« Should Drug Industry Research All Get Rejected For Publication? |
| Abandoning the Chinese Drug Market »
January 16, 2014
Merck Pulls One Out
Merck's vorapaxar, a thrombin antagonist that many had thought might never make it, has received a positive FDA advisory committee vote. I'm glad to see it - peripherally, I go way back with this compound (well, its ancestors), and I really had doubts that Merck could get things to fly. Anticoagulants are a very tricky business - we'll see (if and when it does get approved) what sort of market it can carve out. They're up for treating patient who have already had one cardiac event, which is still a good-sized market.
+ TrackBacks (0) | Category: Cardiovascular Disease | Regulatory Affairs
POST A COMMENT
- RELATED ENTRIES
- A New Olefin Coupling
- Abandoning the Chinese Drug Market
- Merck Pulls One Out
- Should Drug Industry Research All Get Rejected For Publication?
- "We Had to Clear Out Some Chemists"
- A Short Guide to the JP Morgan Conference
- A New Metabolism Predictor
- Trouble With Stapled Peptides? A Strong Rebuttal.